Castle Biosciences to Present at the JMP Securities Life Sciences Conference

Rhea-AI Summary

Castle Biosciences (Nasdaq: CSTL) announces a presentation at the JMP Securities Life Sciences Conference on June 16, 2022, by CEO Derek Maetzold and CFO Frank Stokes at 10:30 a.m. Eastern time. A live audio webcast will be accessible on Castle's website, with a replay available for two weeks post-event. The company focuses on innovative diagnostic tests for various cancers and health conditions, aiming to enhance patient care through advanced solutions. For details, visit CastleBiosciences.com.

FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to present a company overview at the JMP Securities Life Sciences Conference on Thursday, June 16, 2022, at 10:30 a.m. Eastern time.

A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’ website at https://ir.castlebiosciences.com/events-presentations/default.aspx. A replay of the webcast will be available for two weeks following the conclusion of the live broadcast.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle’s current portfolio consists of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, Twitter and Instagram.

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, myPath Melanoma, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220608005264/en/

Investor Contact:

Camilla Zuckero

czuckero@castlebiosciences.com

Media Contact:

Allison Marshall

amarshall@castlebiosciences.com

Source: Castle Biosciences, Inc.

FAQ

When will Castle Biosciences present at the JMP Securities Life Sciences Conference?

Castle Biosciences will present at the JMP Securities Life Sciences Conference on June 16, 2022, at 10:30 a.m. Eastern time.

Who will represent Castle Biosciences at the conference?

CEO Derek Maetzold and CFO Frank Stokes will represent Castle Biosciences at the conference.

How can I listen to Castle Biosciences' presentation?

You can listen to the live audio webcast of Castle Biosciences' presentation on their website, with a replay available for two weeks afterward.

What is the focus of Castle Biosciences' tests?

Castle Biosciences focuses on developing tests for skin cancers, uveal melanoma, Barrett’s esophagus, and mental health conditions.

What is the stock symbol for Castle Biosciences?

The stock symbol for Castle Biosciences is CSTL.